First nonsteroidal treatment approved for patients six years of age and older with DMD regardless of genetic mutation now available in the U.S. ITF also announces the launch of ITF […]
READ THE FULL PRESS RELEASE HERE Introduction The journey towards finding effective treatments for Duchenne Muscular Dystrophy (DMD) has been marked by significant milestones. However, recent findings indicate that we […]
We at CureDuchenne are excited to acknowledge the recent announcement by the United States Food and Drug Administration (FDA) about the creation of the “Rare Disease Innovation Hub.” This new […]
A Father Rises in Support of His Son: On this powerful episode of the “In Sickness” podcast, dad, Josh Argall opens up about the emotional rollercoaster following his son Devin’s […]
Event Has Raised More Than $5.8 Million Over the Last 12 Years to Drive a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (July 12, 2024) — CureDuchenne, a leading […]
There is no excerpt because this is a protected post.
Dyne Therapeutics shares with the community recent efficacy and safety data from the ongoing DELIVER trial of DYNE-251 in Duchenne. Watch HERE
CureDuchenne Webinar | ITF THERAPEUTICS Patient Community Update: An overview of DUVYZAT Recorded on June 26, 2024Watch HERE
Watch HERE
